Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Total nonsense. Most ridiculous post I have ever seen.
Wow!
Opti
no restricted shares.
Opti
No part. They called in their loan in 2002 and brought down the company. Once Cyclops was bankrupt they closed up shop and the shell has sat for 18 years.
Opti
Afraid so. I have over 100 emails from John on NEWC. Always promising good news just around the corner. All he had to do with NEWC was pay for the audit and re-register the ticker. Instead he moved on to a new scam. I fear he has sold his soul to Satan. Yoo has been warning you all about John.
John will pay for this, if not in this life, then in the hereafter. God is not mocked.
Opti
Well, they knew who we were in 2002 when we loaned them money to pay the rent for another month so they could find buyers for the lab equipment. I guess my memory is longer than Stoddard's.
Opti
No need. People do not listen. Don't waste your time.
Opti
beware the term "pre-orders"
Opti
Since we have not received any notification, I assume shareholders received nothing.
Opti
Thomas Howells was the last contact I had from 2010.
He was listed as President at the time.
Opti
There was some company from Utah that took over the company name after the Stoddard crew. I even talked with the head several times on the phone as they were exploring sale of the shell. This was all in the 2004 timeframe, so understandably fuzzy on the details.
Opti
Note: Roger may have been one of the shareholders involved in the loans.
Opti
Back in 2002 I was one of several people that loaned the company $1,000 to pay the rent on the lab to give them time to liquidate all the office equipment.
I was dealing with Neal Rensmeyer and Roger Toland and Durand Smith.
Bill Stoddard was alive at that time, but removed from the company.
Neal died of a heart attack later; I heard this from his widow.
Still checking old files to see if my recollection of Stoddard also dying of a heart attack is accurate.
More if I find it.
Opti
Fearing we are on yet another death swirl back to $8. .30/.35 drop daily for a month, then the MMs will take it back up again to suck us dry on another manipulated missed earnings. Too bad the market is so rigged.
Opti
I always thought the OZON ticker was valuable, but I thought the value would result in a reverse merger, not a payment to have the current owner change the ticker. Even from the grave this one continues to disappoint.
Opti
Romans 14:11-12 (NASB) 11 For it is written, "AS I LIVE, SAYS THE LORD, EVERY KNEE SHALL BOW TO ME, AND EVERY TONGUE SHALL GIVE PRAISE TO GOD." 12 So then each one of us will give an account of himself to God.
John may not give an account of himself and his business to us, but he will to God in the end. That is more fearful.
Opti
I will have to check my old computer for all my OZON files, but I believe Bill Stoddard passed away. I will check tomorrow.
Opti
He is accountable to God.
Opti
Pennsylvania requires testing for incoming visitors: .....starting Friday, anyone who enters Pennsylvania must be tested at least 72 hours before arrival, and if they can or do not get a test, they must quarantine for 14 days. The order does not apply to people who commute to neighboring states for work or health care, officials said, and will be largely self-enforced.
https://www.foxnews.com/us/pa-gov-announces-new-covid-rules-including-wearing-a-mask-in-your-house
Opti
Unfortunately, no. I am concerned for John's soul. He desperately needs to do the right thing. No excuses.
Opti
Galatians 6:7-10 (NASB) 7 Do not be deceived, God is not mocked; for whatever a man sows, this he will also reap. 8 For the one who sows to his own flesh will from the flesh reap corruption, but the one who sows to the Spirit will from the Spirit reap eternal life. 9 Let us not lose heart in doing good, for in due time we will reap if we do not grow weary. 10 So then, while we have opportunity, let us do good to all people, and especially to those who are of the household of the faith.
Opti
The three stocks I watch closely. Current prices:
INO $11.80
APT $12.55
CODX $11.91
Opti
News Release Issued: Nov 17, 2020 (6:30am EST)
To view this release online and get more information about Co-Diagnostics | MediaRoom visit: https://news.codiagnostics.com/2020-11-17-Co-Diagnostics-Inc-Receives-CE-Markings-for-ABC-and-SARS-CoV-2-2-Gene-Multiplex-Tests
Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests
New tests expand global reach of Company COVID-19 test menu
SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart™ SARS-CoV-2 (genes RdRp/E) multiplex test for multiple targets of the SARS-CoV-2 genome have both obtained regulatory authorization to be sold as in vitro diagnostics ("IVD") for the diagnosis of COVID-19 in markets that accept CE-markings, and are now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility.
Co-Diagnostics' Logix Smart ABC test kit allows for simultaneous detection of and differentiation between influenza A, influenza B, and SARS-CoV-2, the virus that causes COVID-19. The Company's SARS-CoV-2 multi-gene test uses two gene markers, RdRp and E-gene to identify the presence SARS-CoV-2, and was designed to meet the demand for tests in regions that prefer multiple targets to confirm a positive diagnosis. Both multiplex tests use the Company's patented CoPrimer™ technology and are designed for use with saliva and other respiratory tract samples, such as nasal swabs or sputum.
Due to the similarity in symptoms between the common cold, the flu, and COVID-19, even vaccinated patients exhibiting any of these related symptoms will still require testing for differentiation. For this reason, the Company believes a durable market will persist for its ABC test long after a COVID-19 vaccine is widely available, and that the test marks the Company's entrance into the high-demand upper respiratory diagnostic space, independent of COVID-19.
Dwight Egan, Chief Executive Officer of Co-Diagnostics, commented, "Since announcing that we were the first American company to receive a CE marking for a COVID-19 diagnostic, Co-Diagnostics has continued to provide high-quality molecular diagnostic solutions for the coronavirus worldwide. We are pleased to now announce additional tools in the ongoing battle against the pandemic, especially for those regions where government or regulatory bodies recommend a multi-target coronavirus diagnostic, such as in India.
"Our CoPrimer technology is ideally suited for multiplexed PCR tests, as it dramatically reduces the possibility of 'primer-dimers,' a common phenomenon in PCR reactions that leads to false positive results, and allowing for assays with much higher specificity. With up to 56 million flu cases in the US alone in the last flu season, and with symptoms that are often similar to those of COVID-19, we believe that the need for a high-quality diagnostic tool capable of accurately detecting and differentiating between flu A/B and COVID-19 while also delivering true-negative results will remain strong.
"Both tests were designed and created in response to demand from our target markets, domestic and abroad. With these CE markings in place, we look forward to continuing our mandate to bring high quality, affordable molecular diagnostics to nations across the world, and to remaining in the forefront of the fight against COVID-19."
The CE Markings for both the Logix Smart ABC Test and the Logix Smart SARS-CoV-2 (genes RdRp/E) test confirm that they meet the Essential Requirements of the European Community's In-Vitro Diagnostic Medical Device Directive (IVDD 98/79/EC), permitting export and sales of the products as IVDs to commence immediately in the European Community. Many other global markets also accept a CE marking as valid regulatory approval following routine local product registration, which allows sales of the Company's IVDs into these areas.
Matthew 16:26-27 (NASB) 26 "For what will it profit a man if he gains the whole world and forfeits his soul? Or what will a man give in exchange for his soul? 27 "For the Son of Man is going to come in the glory of His Father with His angels, and WILL THEN REPAY EVERY MAN ACCORDING TO HIS DEEDS.
Opti
Companies are united in their belief that it’s best not to announce quarterly earnings results during trading hours. About 95% of publicly held companies subscribe to that policy, according to new research.
Among those that do, there’s a fairly even split between earnings announced after the closing bell (i.e., before midnight, chosen by 53% of such companies) and those announced before the opening bell (after midnight, chosen by the rest).
But the timing decision has implications with respect to the market’s reaction to the announcement. That is, earnings releases made before trading opens are associated with greater volatility in stock prices than are those made after trading closes, according to a paper by Northwestern University professor Matt Lyle and three colleagues.
Remarkably, the increased volatility lasts for five days after the announcement, according to the research, which looks at about 70,000 quarterly earnings announcements with precise timestamps from 2006 to 2014. The data was provided by Wall Street Horizon, an earnings announcement tracker.
Specifically, on average the stock of a company that announces earnings in the pre-opening hours is approximately 3.2% more volatile per day during the five-day period, compared to its historical average, than is the stock of a company that announces earnings in the post-closing hours.
Additionally, the team looked at the specific hour when announcements are made. They found that those made close to either the opening or closing bell are less volatile than those made further away from those hours. For example, an announcement made at 6:00 a.m. Eastern time tends to be more volatile than one made at 9:00. The researchers hypothesize that the difference is explained by investors needing time to process the information before factoring it into trading activities.
“All else equal, as investors process information and revise their beliefs, they engage in trade which moves prices,” the paper says. The authors add that the differences in volatility that they document are “highly predictable” and persist even when controlling for many other factors associated with volatility, including company size, profitability, earnings surprises, volume, spreads, and historical volatility.
The researchers further note that option-trading strategies based on buying in the morning and selling at night can produce significant returns. Many CFOs, however, no doubt prefer a lower degree of volatility — an outcome that merely choosing a different hour for disclosing results could help achieve, the research suggests.
Lyle’s co-authors are Christopher Rigsby, a doctoral candidate at Northwestern’s Kellogg School of Management; Andrew Stephan, a professor at the University of Colorado; and Indiana University professor Teri Lombardi Yohn.
https://www.cfo.com/financial-reporting-2/2018/01/whats-the-best-time-to-announce-earnings-announcements/
Opti
“Some people are morning people and some people are afternoon people,” says Jeff Morgan, president of the National Investor Relations Institute. He adds that once a company picks a time, it sticks. “We want to be sure that whatever we do every quarter, we do the same thing the next quarter, so that there’s not anybody wondering why we’re making changes.”
A recent study found that 66 percent of companies hold earnings calls at the same time every quarter. Co-author Elizabeth Demers, an associate professor of accounting at the University of Virginia’s Darden School of Business, says executives should avoid afternoon calls, when they might be hungry and cranky.
“What we find is that as the tone of the calls becomes more negative, the share price returns are also more negative,” Demers says. “In other words, the stock price responds to the negativity that’s being emitted on the calls.”
Demers says size matters, too; a lot of small companies reporting earnings have to take whatever slot they can get.
Opti
Ozone is a great sanitizer. Should work great on COVID virus.
Opti
So, what the heck happened today? It is always something with this stock. Hit just under 17 early then turned down.
If there is another hit piece, we are screwed once again.
Opti
So, what the heck happened today? It is always something with this stock. Hit just under 17 early then turned down.
If there is another hit piece, we are screwed once again.
Opti
Ah, the dreams return
Opti
I also put in a buy order, since I had some money in my account.
Opti
I wrote P&G after they foreclosed on the loan to OZON and received a response from their legal counsel. I still have that letter. This could get interesting.
Opti
5th and most probable explanation.
We are all still asleep and this is just another one of our crazy dreams.
Opti
Why do companies choose to announce earnings before or after the bell? Is there a strategy involved in the decision? Is there an advantage to the company?
Opti
In July we started walking up daily from 19 to 23. Then on August 3rd we suddenly jumped from 22 to a high of the day of 30.99. That was on a volume of 14,454,678. Volume the day before and the day after was 5 million plus. Volume is the key. Note, in August the pps held in the 20’s until August 14, when it dropped to 16.29 from 21 on volume of 9.8 million.
Opti
Watch the volume. In May the high of the day from May 13 to May 15 went, 23.50, 29.72, 21.20. the really big outlier was the volume which was 24,297,284; 52,631,066; and 21,118,901. May 14 was the 52 million volume day with a high of 29.72.
Opti
And the bottle washer, and the navy close washer. Many hopes, all dashed when P&G called in their loan.
Opti
actually, I declared them worthless for a tax write-off and then sold them the next year.
Now I hold worthless shares of NEWC which was delisted because the company failed to file financial audits.
HOWEVER, I am close to cashing in shares of CODX, which hopefully will make up for all my losses.
I guess I am a long-term investor.
Lots of history with OZON; that was a pipe dream that simply had bad fortune.
Opti
cure for COVID.
My 3 million shares will be worth $300 million.
Opti
So, we started Monday at $14.41, before the big drop on the vaccine news. Was that big drop just an excuse to give the shorts some room to cover? Are we now set for a run tomorrow and Monday? Is this the time we actually increase pps after earnings? Or are we going to get played once again?
How can you trust the market when we have been burned on this stock two times before on earnings report reactions? What trick is sitting out there waiting to be pulled this time?
Opti
Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction
SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™ platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample, and can do so while providing low limits of detection.
The technical advance featured in the whitepaper, found here, was the result of a study into the compatibility of CoPrimer technology with detection of SARS-CoV-2 directly from raw saliva. Various CoPrimer assay configurations were used to consistently detect SARS-CoV-2 in minimally processed saliva in the whitepaper, which concludes that CoPrimers provide a robust platform for the development of such tests.
Dwight Egan, CEO of Co-Diagnostics, commented, "The market for high-throughput, cost-effective COVID-19 tests continues to be strong, and eliminating the costly and time-consuming RNA extraction step allows for even greater speed and economic advantages. We believe the conclusions of this whitepaper speak to the strength, innovation, and flexibility of our CoPrimer platform not just as it relates to creating improved testing technology for COVID-19, but also additional possibilities to implement CoPrimers in various other diagnostic applications. Our next steps include incorporating extraction-free saliva direct tests into the Company product offerings, including those for COVID-19, so they can be available to our customer base world-wide."
Release of the Company whitepaper follows recent news that Clinical Reference Laboratory (CRL) is now selling its CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers. The CRL announcement states that the test uses CoPrimer probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting, with results in typically 24 hours that are delivered via a secure online computer or mobile device platform.
Mr. Egan continued, "CRL has been an invaluable customer and partner in providing high-quality molecular diagnostic COVID-19 tests to individuals and organizations across the country, helping to facilitate the safe reopening of schools, business, and other organizations. We are pleased that its CRL Rapid Response test will now be even more widely available to consumers online."
Co-Diagnostics' existing CE-marked and FDA EUA Logix Smart COVID-19 test is available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries.
https://news.codiagnostics.com/2020-11-11-Co-Diagnostics-Inc-CoPrimers-TM-Shown-to-be-Effective-in-COVID-19-Saliva-PCR-Tests-Without-Sample-Extraction
Opti